Cheryl Chandler, PA
Urology · Taunton, MANPI 1609800085
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 119 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $775 and has fallen 55.9% since, to $342 in 2025.
Across 119 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$532
- AbbVie$511
- GSK$501
- Sumitomo Pharma America, Inc.$159
- Astellas Pharma US Inc$137
- Dentsply IH Inc.$105
- plus $513 from 14 others
What the payments were for
- Food & beverage$2,39597%
- Education$623%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 24 | $532 |
| AbbVie | 21 | $511 |
| GSK | 30 | $501 |
| Sumitomo Pharma America, Inc. | 7 | $159 |
| Astellas Pharma US Inc | 5 | $137 |
| Dentsply IH Inc. | 6 | $105 |
| Pfizer | 5 | $83 |
| Telix Pharmaceuticals | 3 | $74 |
| Amgen | 2 | $58 |
| AstraZeneca | 2 | $45 |
| Novo Nordisk | 2 | $42 |
| Boehringer Ingelheim | 2 | $39 |
| Antares Pharma, Inc. | 2 | $38 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $29 |
| Urovant Sciences Inc | 1 | $21 |
| Acerus Pharmaceuticals Corporation | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Halozyme Inc | 1 | $17 |
| Medtronic | 1 | $16 |
| Rochester Medical Corporation | 1 | $14 |
How this compares
$2,457 in reported general payments places this provider in the 55th percentile of 327 urology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 535 | $405,376 |
| MyrbetriqMirabegron | 292 | $187,530 |
| Mirabegron ErMirabegron | 39 | $14,647 |
| Tamsulosin Hcl | 622 | $13,185 |
| XyostedTestosterone Enanthate | 19 | $11,768 |
| Methenamine Hippurate | 140 | $9,156 |
| Solifenacin Succinate | 98 | $5,772 |
| Finasteride | 296 | $5,129 |
| Oxybutynin Chloride ErOxybutynin Chloride | 162 | $4,184 |
| Tolterodine Tartrate ErTolterodine Tartrate | 26 | $2,900 |
| Potassium Citrate ErPotassium Citrate | 30 | $2,669 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 74 | $2,108 |
| Oxybutynin Chloride | 49 | $1,468 |
| Testosterone | 22 | $1,374 |
| Estradiol | 28 | $1,322 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $159 | $405,376535 claims |
| Astellas Pharma US IncMyrbetriq | $137 | $187,530292 claims |
| Antares Pharma, Inc.Xyosted | $38 | $11,76819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 327 urology providers in Massachusetts.
Other urology in Taunton
- Christopher CutieBoston$3.5M
- Brian EisnerBoston$424K
- David StaskinBrighton$407K
- Liam HurleyNorth Andover$319K
- Stephen DretlerBoston$298K
- Abraham MorgentalerChestnut Hill$290K
- Louis LiouCambridge$278K
- Tony LuongoBoston$265K
- Ricardo MunarrizBoston$118K
- Andrew KramerHyannis$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.